Last edition
News about "U.S. Over Cancer Biosimilar Patent Dispute"
Zydus Lifesciences Hit by Legal Setback in U.S. Over Cancer Biosimilar Patent Dispute
While Zydus may consider appealing the verdict or negotiating a settlement, the setback highlights the broader challenges biosimilar manufacturers face in penetrating regulated markets like the U.S.
U.S. Over Cancer Biosimilar Patent Dispute | 21/07/2025 | By Darshana | 238
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members